Soleno Therapeutics, Inc. (SLNO) Stock Analysis & Investment Frameworks
Soleno Therapeutics, Inc. (SLNO) stock analysis on Invetso. Review Soleno Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Soleno Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Soleno Therapeutics, Inc. Key Financial Metrics
- Market Cap: $2.76B
- Revenue: $190.41M
- P/E Ratio: 132.52
- ROE: 22.86%
- ROIC: 15.35%
- Dividend Yield: N/A
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Soleno Therapeutics, Inc. Investment Frameworks
Invetso analyzes Soleno Therapeutics, Inc. (SLNO) across the following frameworks:
- Soleno Therapeutics, Inc. 10Y Growth Potential
- Soleno Therapeutics, Inc. Scenario Analysis
- Soleno Therapeutics, Inc. Risks & Opportunities
- Soleno Therapeutics, Inc. Economic Moat
- Soleno Therapeutics, Inc. Business Model
- Soleno Therapeutics, Inc. Management
- Soleno Therapeutics, Inc. SWOT Analysis
- Soleno Therapeutics, Inc. Porter's 5 Forces
- Soleno Therapeutics, Inc. PESTLE Analysis
- Soleno Therapeutics, Inc. ESG Analysis